Literature DB >> 34147124

Dihydromyricetin ameliorates liver fibrosis via inhibition of hepatic stellate cells by inducing autophagy and natural killer cell-mediated killing effect.

Xi Zhou1, Li Yu1, Min Zhou1, Pengfei Hou1, Long Yi2, Mantian Mi3.   

Abstract

BACKGROUND: This study investigated the mechanisms underlying the preventive effect of dihydromyricetin (DHM) against liver fibrosis involving hepatic stellate cells (HSCs) and hepatic natural killer (NK) cells.
METHODS: A carbon tetrachloride (CCl4)-induced liver fibrosis model was established in C57BL/6 mice to study the antifibrotic effect of DHM based on serum biochemical parameters, histological and immunofluorescence stainings, and the expression of several fibrosis-related markers. Based on the immunoregulatory role of DHM, the effect of DHM on NK cell activation ex vivo was evaluated by flow cytometry. Then, we investigated whether DHM-induced autophagy was involved in HSCs inactivation using enzyme-linked immunosorbent assays, transmission electron microscopy, and western blot analysis. Thereafter, the role of DHM in NK cell-mediated killing was studied by in vitro coculture of NK cells and HSCs, with subsequent analysis by flow cytometry. Finally, the mechanism by which DHM regulates NK cells was studied by western blot analysis.
RESULTS: DHM ameliorated liver fibrosis in C57BL/6 mice, as characterized by decreased serum alanine transaminase and aspartate transaminase levels, decreased expressions of collagen I alpha 1 (CoL-1α1), collagen I alpha 2 (CoL-1α2), tissue inhibitor of metalloproteinases 1 (TIMP-1), α-smooth muscle actin (α-SMA) and desmin, as well as increased expression of matrix metalloproteinase 1 (MMP1). Interestingly, HSCs activation was significantly inhibited by DHM in vivo and in vitro. As expected, DHM also upregulated autophagy-related indicators in liver from CCl4-treated mice. DHM also prevented TGF-β1-induced activation of HSCs in vitro by initiating autophagic flux. In contrast, the autophagy inhibitor 3-methyladenine markedly abolished the antifibrotic effect of DHM. Surprisingly, the frequency of activated intrahepatic NK cells was significantly elevated by DHM ex vivo. Furthermore, DHM enhanced NK cell-mediated killing of HSCs by increasing IFN-γ expression, which was abolished by an anti-IFN-γ neutralizing antibody. Mechanistically, DHM-induced IFN-γ expression was through AhR-NF-κB/STAT3 pathway in NK cells.
CONCLUSION: These results demonstrated that DHM can ameliorate the progression of liver fibrosis and inhibition of HSCs activation by inducing autophagy and enhancing NK cell-mediated killing through the AhR-NF-κB/STAT3-IFN-γ signaling pathway, providing new insights into the preventive role of DHM in liver fibrosis.

Entities:  

Keywords:  Dihydromyricetin; Hepatic stellate cells; IFN-γ; Liver fibrosis; Natural killer cells

Year:  2021        PMID: 34147124     DOI: 10.1186/s12986-021-00589-6

Source DB:  PubMed          Journal:  Nutr Metab (Lond)        ISSN: 1743-7075            Impact factor:   4.169


  59 in total

Review 1.  Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives.

Authors:  Federico Salomone; Justyna Godos; Shira Zelber-Sagi
Journal:  Liver Int       Date:  2015-11-05       Impact factor: 5.828

2.  Dihydromyricetin Ameliorates Nonalcoholic Fatty Liver Disease by Improving Mitochondrial Respiratory Capacity and Redox Homeostasis Through Modulation of SIRT3 Signaling.

Authors:  Xianglong Zeng; Jining Yang; Ou Hu; Juan Huang; Li Ran; Mengting Chen; Yu Zhang; Xi Zhou; Jundong Zhu; Qianyong Zhang; Long Yi; Mantian Mi
Journal:  Antioxid Redox Signal       Date:  2018-02-21       Impact factor: 8.401

3.  Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial.

Authors:  Shihui Chen; Xiaolan Zhao; Jing Wan; Li Ran; Yu Qin; Xiaofang Wang; Yanxiang Gao; Furong Shu; Yong Zhang; Peng Liu; Qianyong Zhang; Jundong Zhu; Mantian Mi
Journal:  Pharmacol Res       Date:  2015-05-30       Impact factor: 7.658

Review 4.  Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies.

Authors:  Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Trends Endocrinol Metab       Date:  2016-12-13       Impact factor: 12.015

Review 5.  Current efforts and trends in the treatment of NASH.

Authors:  Vlad Ratziu; Zachary Goodman; Arun Sanyal
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

6.  Antioxidant activities of Vine Tea (Ampelopsis grossedentata) extract and its major component dihydromyricetin in soybean oil and cooked ground beef.

Authors:  Liyun Ye; Hengjian Wang; Susan E Duncan; William N Eigel; Sean F O'Keefe
Journal:  Food Chem       Date:  2014-09-28       Impact factor: 7.514

Review 7.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

8.  Dihydromyricetin alleviates carbon tetrachloride-induced acute liver injury via JNK-dependent mechanism in mice.

Authors:  Jun Xie; Jie Liu; Tu-Ming Chen; Qing Lan; Qing-Yu Zhang; Bin Liu; Dong Dai; Wei-Dong Zhang; Li-Ping Hu; Run-Zhi Zhu
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

Review 9.  Liver fibrosis.

Authors:  Ramón Bataller; David A Brenner
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

10.  Metabolomics reveals the protective of Dihydromyricetin on glucose homeostasis by enhancing insulin sensitivity.

Authors:  Liang Le; Baoping Jiang; Wenting Wan; Wei Zhai; Lijia Xu; Keping Hu; Peigen Xiao
Journal:  Sci Rep       Date:  2016-10-31       Impact factor: 4.379

View more
  3 in total

1.  Dihydromyricetin Alleviates Pulmonary Fibrosis by Regulating Abnormal Fibroblasts Through the STAT3/p-STAT3/GLUT1 Signaling Pathway.

Authors:  Zhen Li; Jing Geng; Bingbing Xie; Jiarui He; Jing Wang; Liang Peng; Yinan Hu; Huaping Dai; Chen Wang
Journal:  Front Pharmacol       Date:  2022-03-14       Impact factor: 5.810

2.  Alcohol-associated fibrosis in females is mediated by female-specific activation of lysine demethylases KDM5B and KDM5C.

Authors:  Michael Schonfeld; Janice Averilla; Sumedha Gunewardena; Steven A Weinman; Irina Tikhanovich
Journal:  Hepatol Commun       Date:  2022-04-25

3.  Dihydromyricetin-Encapsulated Liposomes Inhibit Exhaustive Exercise-Induced Liver Inflammation by Orchestrating M1/M2 Macrophage Polarization.

Authors:  Xi Zhou; Long Yi; Hedong Lang; Jun Zhang; Qianyong Zhang; Li Yu; Jundong Zhu; Mantian Mi
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.